Displaying drugs 251 - 275 of 13792 in total
Tepotinib
Tepotinib is a MET tyrosine kinase inhibitor intended to treat a variety of MET-overexpressing solid tumors. It was originally developed in partnership between EMD Serono and the University of Texas M.D. Anderson Cancer Center in 2009 and has since been investigated in the treatment of neuroblastoma, gastric cancers, non-small cell...
Approved
Investigational
Matched Iupac: … 3-{1-[(3-{5-[(1-methylpiperidin-4-yl)methoxy]pyrimidin-2-yl}phenyl)methyl]-6-oxo-1,6-dihydropyridazin …
Matched Description: … MET_ exon 14 skipping alterations. ... Anderson Cancer Center in 2009 and has since been investigated in the treatment of neuroblastoma,[A228053 ... critical role, both directly and indirectly, in the growth and proliferation of tumors in which it is …
Matched Categories: … MATE 2 Inhibitors …
Matched Description: … MET_ exon 14 skipping alterations. ... Anderson Cancer Center in 2009 and has since been investigated in the treatment of neuroblastoma,[A228053 ... critical role, both directly and indirectly, in the growth and proliferation of tumors in which it is …
Matched Categories: … MATE 2 Inhibitors …
Budesonide
Budesonide is a glucocorticoid that is a mix of the 22R and 22S epimer used to treat inflammatory conditions of the lungs and intestines such as asthma, COPD, Crohn's disease, and ulcerative colitis.[A188529,A188532]
Budesonide was granted FDA approval on 14 February 1994. It is also available in a combination product...
Approved
Matched Iupac: … (1S,2S,4R,8S,9S,11S,12S,13R)-11-hydroxy-8-(2-hydroxyacetyl)-9,13-dimethyl-6-propyl-5,7-dioxapentacyclo …
Matched Description: … [L10598] It is also available in a combination product with [formoterol].[L10619] ... of the lungs and intestines such as asthma, COPD, Crohn's disease, and ulcerative colitis. ... Budesonide is a glucocorticoid that is a mix of the 22R and 22S epimer used to treat inflammatory conditions …
Matched Mixtures name: … POENA 2/400 MCG İNHALASYON İÇİN TOZ İÇEREN BLİSTER, 60 DOZ ... POENA 2/400 MCG INHALASYON IÇIN TOZ IÇEREN KAPSÜL ,60 KAPSÜL ... POENA 2/400 MCG INHALASYON IÇIN TOZ IÇEREN KAPSÜL ,120 KAPSÜL …
Matched Products: … PULMICORT RESPULES (1 MG IN 2 ML) ... PULMICORT RESPULES (0.5 MG IN 2 ML) ... ENTOCORT(R)2 MG …
Matched Description: … [L10598] It is also available in a combination product with [formoterol].[L10619] ... of the lungs and intestines such as asthma, COPD, Crohn's disease, and ulcerative colitis. ... Budesonide is a glucocorticoid that is a mix of the 22R and 22S epimer used to treat inflammatory conditions …
Matched Mixtures name: … POENA 2/400 MCG İNHALASYON İÇİN TOZ İÇEREN BLİSTER, 60 DOZ ... POENA 2/400 MCG INHALASYON IÇIN TOZ IÇEREN KAPSÜL ,60 KAPSÜL ... POENA 2/400 MCG INHALASYON IÇIN TOZ IÇEREN KAPSÜL ,120 KAPSÜL …
Matched Products: … PULMICORT RESPULES (1 MG IN 2 ML) ... PULMICORT RESPULES (0.5 MG IN 2 ML) ... ENTOCORT(R)2 MG …
Burosumab
Burosumab (KRN23) is an entirely human monoclonal IgG1 antibody that binds excess fibroblast growth factor 23 (FGF23) and has been successfully tested in clinical trials in children with X-linked hypophosphatemic rickets .
The U.S. Food and Drug Administration approved Crysvita (burosumab) in April 2018. This is the first drug approved...
Approved
Investigational
Matched Description: … X-linked hypophosphatemia causes low circulating levels of phosphorus in the blood. ... children ages 1 year and older with X-linked hypophosphatemia (XLH), which is a rare, inherited form of ... Food and Drug Administration approved Crysvita (burosumab) in April 2018. …
Matched Categories: … Drugs for Treatment of Bone Diseases …
Matched Categories: … Drugs for Treatment of Bone Diseases …
Tafamidis
Tafamidis and tafamidis meglumine (FX-1006A) are benzoxazole derivatives developed by FoldRX. Tafamidis is structurally similar to diflusinal. Tafamidis was granted an EMA market authorisation on 16 November 2011 and FDA approval on 3 May 2019.
Approved
Investigational
Matched Iupac: … 2-(3,5-dichlorophenyl)-1,3-benzoxazole-6-carboxylic acid …
Matched Categories: … Heterocyclic Compounds, 2-Ring …
Matched Categories: … Heterocyclic Compounds, 2-Ring …
Erlotinib
Erlotinib is an inhibitor of the epidermal growth factor receptor (EGFR) tyrosine kinase that is used in the treatment of non-small cell lung cancer, pancreatic cancer and several other types of cancer. It is typically marketed under the trade name Tarceva. Erlotinib binds to the epidermal growth factor receptor (EGFR)...
Approved
Investigational
Matched Synonyms: … [6,7-Bis-(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)-amine …
Matched Iupac: … N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine …
Matched Description: … in the treatment of non-small cell lung cancer, pancreatic cancer and several other types of cancer. ... This finding introduces the potential use of erlotinib in the treatment of JAK2V617F-positive PV and ... form of tyrosine kinase JAK2 found in most patients with polycythemia vera (PV) and a substantial proportion …
Matched Categories: … Heterocyclic Compounds, 2-Ring …
Matched Iupac: … N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine …
Matched Description: … in the treatment of non-small cell lung cancer, pancreatic cancer and several other types of cancer. ... This finding introduces the potential use of erlotinib in the treatment of JAK2V617F-positive PV and ... form of tyrosine kinase JAK2 found in most patients with polycythemia vera (PV) and a substantial proportion …
Matched Categories: … Heterocyclic Compounds, 2-Ring …
Dacomitinib
Dacomitinib, designed as (2E)-N-16-4-(piperidin-1-yl) but-2-enamide, is an oral highly selective quinazalone part of the second-generation tyrosine kinase inhibitors which are characterized by the irreversible binding at the ATP domain of the epidermal growth factor receptor family kinase domains. Dacomitinib was developed by Pfizer Inc and approved by the FDA on...
Approved
Investigational
Matched Iupac: … (2E)-N-{4-[(3-chloro-4-fluorophenyl)amino]-7-methoxyquinazolin-6-yl}-4-(piperidin-1-yl)but-2-enamide …
Matched Description: … [L4810] Some evidence in the literature suggests the therapeutic potential of dacomitinib in the epithelial ... Dacomitinib, designed as (2E)-N-16-4-(piperidin-1-yl) but-2-enamide, is an oral highly selective quinazalone ... binding at the ATP domain of the epidermal growth factor receptor family kinase domains. …
Matched Categories: … Heterocyclic Compounds, 2-Ring …
Matched Description: … [L4810] Some evidence in the literature suggests the therapeutic potential of dacomitinib in the epithelial ... Dacomitinib, designed as (2E)-N-16-4-(piperidin-1-yl) but-2-enamide, is an oral highly selective quinazalone ... binding at the ATP domain of the epidermal growth factor receptor family kinase domains. …
Matched Categories: … Heterocyclic Compounds, 2-Ring …
Infigratinib
Infigratinib is a pan-fibroblast growth factor receptor (FGFR) kinase inhibitor. By inhibiting the FGFR pathway, which is often aberrated in cancers such as cholangiocarcinoma, infigratinib suppresses tumour growth. Cholangiocarcinoma is the most common primary malignancy affecting the biliary tract and the second most common primary hepatic malignancy. Infitratinib is a...
Approved
Investigational
Matched Iupac: … 3-(2,6-dichloro-3,5-dimethoxyphenyl)-1-(6-{[4-(4-ethylpiperazin-1-yl)phenyl]amino}pyrimidin-4-yl)-1-methylurea …
Matched Description: … fibroblast growth factor receptor 2 (FGFR2) fusion or another rearrangement as detected by an FDA-approved ... By inhibiting the FGFR pathway, which is often aberrated in cancers such as cholangiocarcinoma, infigratinib ... [A198963] Infitratinib is a pan-FGFR inhibitor, as it is an ATP-competitive inhibitor of all four FGFR …
Matched Salts cas: … 1310746-15-6 …
Matched Categories: … MATE 2 Inhibitors ... Fibroblast Growth Factor 2, antagonists & inhibitors …
Matched Description: … fibroblast growth factor receptor 2 (FGFR2) fusion or another rearrangement as detected by an FDA-approved ... By inhibiting the FGFR pathway, which is often aberrated in cancers such as cholangiocarcinoma, infigratinib ... [A198963] Infitratinib is a pan-FGFR inhibitor, as it is an ATP-competitive inhibitor of all four FGFR …
Matched Salts cas: … 1310746-15-6 …
Matched Categories: … MATE 2 Inhibitors ... Fibroblast Growth Factor 2, antagonists & inhibitors …
Gaxilose
Gaxilose has been used in trials studying the diagnostic of Lactose Intolerance.
Approved
Investigational
Matched Iupac: … (2R,3R,4R)-2,3,5-trihydroxy-4-{[(2S,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}pentanal …
Matched Description: … Gaxilose has been used in trials studying the diagnostic of Lactose Intolerance. …
Matched Description: … Gaxilose has been used in trials studying the diagnostic of Lactose Intolerance. …
Bisacodyl
Bisacodyl, a diphenylmethane derivative, is a commonly used over the counter stimulant laxative for occasional constipation.[A233300,L13362] Both bisacodyl and picosulfate are metabolized to the same active metabolite bis-(p-hydroxyphenyl)-pyridyl-2-methane (BHPM).[A233290,A233300,A207700]
Bisacodyl was patented on 25 September 1956 but has been used as a laxative since 1952.
Approved
Matched Synonyms: … Phenol, 4,4'-(2-pyridinylmethylene)bis-, diacetate (ester) …
Matched Iupac: … 4-{[4-(acetyloxy)phenyl](pyridin-2-yl)methyl}phenyl acetate …
Matched Description: … bisacodyl and [picosulfate] are metabolized to the same active metabolite bis-(p-hydroxyphenyl)-pyridyl-2- …
Matched Products: … LAKSOTEK SUPPOZİTUAR, 6 ADET ... LAKSOTEK PEDİATRİK SUPPOZİTUAR, 6 ADET …
Matched Iupac: … 4-{[4-(acetyloxy)phenyl](pyridin-2-yl)methyl}phenyl acetate …
Matched Description: … bisacodyl and [picosulfate] are metabolized to the same active metabolite bis-(p-hydroxyphenyl)-pyridyl-2- …
Matched Products: … LAKSOTEK SUPPOZİTUAR, 6 ADET ... LAKSOTEK PEDİATRİK SUPPOZİTUAR, 6 ADET …
Meclofenamic acid
A non-steroidal anti-inflammatory agent with antipyretic and antigranulation activities. It also inhibits prostaglandin biosynthesis.
Approved
Vet approved
Matched Iupac: … 2-[(2,6-dichloro-3-methylphenyl)amino]benzoic acid …
Matched Categories: … Non COX-2 selective NSAIDS …
Matched Categories: … Non COX-2 selective NSAIDS …
Influenza A virus A/Hong Kong/2671/2019 NIB-121 (H3N2) antigen (UV, formaldehyde inactivated)
A seasonally-specific component of the influenza vaccine. The influenza vaccine, also known as the "flu shot", is a vaccine that protects against infection from the influenza viruses. Vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence...
Approved
Matched Description: … Inactivated vaccines contain a virus particle that has been grown in media and then subsequently killed ... In contrast, live vaccines are produced from "wild-type" or disease-causing viruses that have been attenuated ... Inactivated virus cannot replicate, and therefore cannot cause disease from infection, even in immunocompromised …
Tapentadol
Tapentadol is a centrally-acting synthetic analgesic with a dual mechanism of action. It is a mu-opioid receptor agonist that also inhibits norepinephrine reuptake.[A260721, A36596]
Tapentadol was first approved by the FDA on November 20, 2008. The extended-release formulation of tapentadol was also approved by the FDA on August 26, 2011....
Approved
Matched Synonyms: … 3-[(1R,2R)-3-(Dimethylamino)-1-ethyl-2-methylpropyl]phenol ... PHENOL, 3-((1R,2R)-3-(DIMETHYLAMINO)-1-ETHYL-2-METHYLPROPYL)- …
Matched Iupac: … 3-[(2R,3R)-1-(dimethylamino)-2-methylpentan-3-yl]phenol …
Matched Description: … [L47291] Used in the management of pain, tapentadol is typically reserved for patients who have limited ... Tapentadol is a centrally-acting synthetic analgesic with a dual mechanism of action. ... The extended-release formulation of tapentadol was also approved by the FDA on August 26, 2011. …
Matched Categories: … Combined Inhibitors of Serotonin/Norepinephrine Reuptake ... Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome …
Matched Iupac: … 3-[(2R,3R)-1-(dimethylamino)-2-methylpentan-3-yl]phenol …
Matched Description: … [L47291] Used in the management of pain, tapentadol is typically reserved for patients who have limited ... Tapentadol is a centrally-acting synthetic analgesic with a dual mechanism of action. ... The extended-release formulation of tapentadol was also approved by the FDA on August 26, 2011. …
Matched Categories: … Combined Inhibitors of Serotonin/Norepinephrine Reuptake ... Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome …
Azatadine
Antihistamines such as azatadine appear to compete with histamine for histamine H1- receptor sites on effector cells. The antihistamines antagonize those pharmacological effects of histamine which are mediated through activation of H1- receptor sites and thereby reduce the intensity of allergic reactions and tissue injury response involving histamine release.
Approved
Matched Iupac: … 2-(1-methylpiperidin-4-ylidene)-4-azatricyclo[9.4.0.0^{3,8}]pentadeca-1(15),3(8),4,6,11,13-hexaene …
Matched Description: … of H1- receptor sites and thereby reduce the intensity of allergic reactions and tissue injury response ... The antihistamines antagonize those pharmacological effects of histamine which are mediated through activation …
Matched Description: … of H1- receptor sites and thereby reduce the intensity of allergic reactions and tissue injury response ... The antihistamines antagonize those pharmacological effects of histamine which are mediated through activation …
Haemophilus influenzae type B strain 20752 capsular polysaccharide tetanus toxoid conjugate antigen
Haemophilus influenzae type b strain 20752 capsular polysaccharide tetanus toxoid conjugate antigen is an active immunization as a booster dose given intramuscularly to pediatric patients who have received a primary series with a Haemophilus b Conjugate Vaccine that is licensed for primarly immunization. The vaccine contains Haemophilus b capsular polysaccharide...
Approved
Investigational
Holcus lanatus pollen
Holcus lanatus pollen is the pollen of the Holcus lanatus plant. Holcus lanatus pollen is mainly used in allergenic testing.
Approved
Matched Description: … Holcus lanatus pollen is mainly used in allergenic testing. ... Holcus lanatus pollen is the pollen of the Holcus lanatus plant. …
Matched Mixtures name: … Mixture of Standardized and Non-Standardized Coastal Grasses ... Mixture of Twenty-Two Standardized and Non-Standardized Grasses …
Matched Mixtures name: … Mixture of Standardized and Non-Standardized Coastal Grasses ... Mixture of Twenty-Two Standardized and Non-Standardized Grasses …
Cefmetazole
A semisynthetic cephamycin antibiotic with a broad spectrum of activity against both gram-positive and gram-negative microorganisms. It has a high rate of efficacy in many types of infection and to date no severe side effects have been noted.
Approved
Investigational
Matched Synonyms: … ene-2-carboxylic acid ... amino)-7-methoxy-3-{[(1-methyl-1H-tetrazol-5-yl)sulfanyl]methyl}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2- …
Matched Iupac: … ]methyl}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid ... (6R,7S)-7-{2-[(cyanomethyl)sulfanyl]acetamido}-7-methoxy-3-{[(1-methyl-1H-1,2,3,4-tetrazol-5-yl)sulfanyl …
Matched Description: … It has a high rate of efficacy in many types of infection and to date no severe side effects have been ... A semisynthetic cephamycin antibiotic with a broad spectrum of activity against both gram-positive and …
Matched Categories: … Heterocyclic Compounds, 2-Ring …
Matched Iupac: … ]methyl}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid ... (6R,7S)-7-{2-[(cyanomethyl)sulfanyl]acetamido}-7-methoxy-3-{[(1-methyl-1H-1,2,3,4-tetrazol-5-yl)sulfanyl …
Matched Description: … It has a high rate of efficacy in many types of infection and to date no severe side effects have been ... A semisynthetic cephamycin antibiotic with a broad spectrum of activity against both gram-positive and …
Matched Categories: … Heterocyclic Compounds, 2-Ring …
Polatuzumab vedotin
Polatuzumab vedotin is a CD79b-directed antibody-drug conjugate that delivers monomethyl auristatin E (MMAE), an anti-mitotic agent, to cancer cells. The drug consists of three components - a humanized immunoglobulin G1 (IgG1) monoclonal antibody specific for human CD79b (polatuzumab), MMAE, and protease-cleavable linker called maleimidocaproyl-valine-citrulline-p-aminobenzyloxycarbonyl (mc-vc-PAB) that covalently attaches MMAE to...
Approved
Investigational
Matched Description: … [L6658] The drug consists of three components - a humanized immunoglobulin G1 (IgG1) monoclonal antibody …
Alfuzosin
Benign prostatic hyperplasia (BPH) refers to a benign growth or hyperplasia of the prostate and leads to lower urinary tract symptoms in men, such as urgency, frequency and changes to urine flow. The prevalence of BPH is as high as 50%-60% for males in their 60's, and this prevalence increases...
Approved
Investigational
Matched Synonyms: … (±)-N-[3-[(4-amino-6,7-dimethoxy-2-quinazolinyl)methylamino]propyl]tetrahydro-2-furamide ... N-[3-[(4-amino-6,7-dimethoxy-quinazolin-2-yl)- methyl-amino]propyl] tetrahydrofuran- 2-carboxamide …
Matched Iupac: … N-{3-[(4-amino-6,7-dimethoxyquinazolin-2-yl)(methyl)amino]propyl}oxolane-2-carboxamide …
Matched Description: … The prevalence of BPH is as high as 50%-60% for males in their 60's, and this prevalence increases to ... [A228483] Alfuzosin is an alpha-1 adrenergic blocker used in the symptomatic treatment of BPH that works ... 80%-90% of those over 70. …
Matched Categories: … Heterocyclic Compounds, 2-Ring ... Drugs Used in Benign Prostatic Hypertrophy …
Matched Iupac: … N-{3-[(4-amino-6,7-dimethoxyquinazolin-2-yl)(methyl)amino]propyl}oxolane-2-carboxamide …
Matched Description: … The prevalence of BPH is as high as 50%-60% for males in their 60's, and this prevalence increases to ... [A228483] Alfuzosin is an alpha-1 adrenergic blocker used in the symptomatic treatment of BPH that works ... 80%-90% of those over 70. …
Matched Categories: … Heterocyclic Compounds, 2-Ring ... Drugs Used in Benign Prostatic Hypertrophy …
Nimodipine
Nimodipine is a 1,4-dihydropyridine calcium channel blocker. It acts primarily on vascular smooth muscle cells by stabilizing voltage-gated L-type calcium channels in their inactive conformation. By inhibiting the influx of calcium in smooth muscle cells, nimodipine prevents calcium-dependent smooth muscle contraction and subsequent vasoconstriction. Compared to other calcium channel blocking...
Approved
Investigational
Matched Synonyms: … isopropyl 2-methoxyethyl 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridinedicarboxylate ... isopropyl 2-methoxyethyl 1,4-dihydro-2,6-dimethyl-4-(m-nitrophenyl)-3,5-pyridinedicarboxylate …
Matched Iupac: … 3-(2-methoxyethyl) 5-propan-2-yl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate …
Matched Description: … By inhibiting the influx of calcium in smooth muscle cells, nimodipine prevents calcium-dependent smooth ... acts primarily on vascular smooth muscle cells by stabilizing voltage-gated L-type calcium channels in …
Matched Iupac: … 3-(2-methoxyethyl) 5-propan-2-yl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate …
Matched Description: … By inhibiting the influx of calcium in smooth muscle cells, nimodipine prevents calcium-dependent smooth ... acts primarily on vascular smooth muscle cells by stabilizing voltage-gated L-type calcium channels in …
Ertugliflozin
Ertugliflozin is a sodium-dependent glucose cotransporter-2 (SGLT2) inhibitor used to treat type II diabetes mellitus. It works to block glucose reabsorption from the glomerulus. Ertugliflozin was first approved by the FDA in December 2017.[A261951, L1132] It was also approved by the European Commission in March 2018.
Approved
Investigational
Matched Description: … Ertugliflozin is a sodium-dependent glucose cotransporter-2 (SGLT2) inhibitor used to treat type II diabetes ... [A31581]
Ertugliflozin was first approved by the FDA in December 2017. ... [A261951, L1132] It was also approved by the European Commission in March 2018.[L48621] …
Matched Categories: … Drugs Used in Diabetes ... Sodium-Glucose Transporter 2 Inhibitors ... Sodium-glucose Cotransporter 2 (SGLT2) Inhibitors …
Matched Categories: … Drugs Used in Diabetes ... Sodium-Glucose Transporter 2 Inhibitors ... Sodium-glucose Cotransporter 2 (SGLT2) Inhibitors …
Indacaterol
Indacaterol is a novel, ultra-long-acting, rapid onset β(2)-adrenoceptor agonist developed for Novartis for the once-daily management of asthma and chronic obstructive pulmonary disease. It was approved by the European Medicines Agency (EMA) on 30 November 2009 and by the FDA on 1 July 2011. It is marketed in Europe as...
Approved
Matched Iupac: … -2-one ... 5-[(1R)-2-[(5,6-diethyl-2,3-dihydro-1H-inden-2-yl)amino]-1-hydroxyethyl]-8-hydroxy-1,2-dihydroquinolin …
Matched Description: … It is marketed in Europe as Onbrez and in America as Arcapta Neohaler. ... for the once-daily management of asthma and chronic obstructive pulmonary disease. ... Indacaterol is a novel, ultra-long-acting, rapid onset β(2)-adrenoceptor agonist developed for Novartis …
Matched Salts cas: … 1000160-96-2 …
Matched Categories: … Adrenergic beta-2 Receptor Agonists ... Heterocyclic Compounds, 2-Ring ... Selective Beta 2-adrenergic Agonists …
Matched Description: … It is marketed in Europe as Onbrez and in America as Arcapta Neohaler. ... for the once-daily management of asthma and chronic obstructive pulmonary disease. ... Indacaterol is a novel, ultra-long-acting, rapid onset β(2)-adrenoceptor agonist developed for Novartis …
Matched Salts cas: … 1000160-96-2 …
Matched Categories: … Adrenergic beta-2 Receptor Agonists ... Heterocyclic Compounds, 2-Ring ... Selective Beta 2-adrenergic Agonists …
Linagliptin
Linagliptin is a DPP-4 inhibitor developed by Boehringer Ingelheim for the treatment of type II diabetes . Linagliptin differs from other DPP-4 inhibitors in that it has a non-linear pharmacokinetic profile, is not primarily eliminated by the renal system, and obeys concentration dependant protein binding . Linagliptin was approved by...
Approved
Matched Synonyms: … (R)-8-(3-aminopiperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methylquinazolin-2-ylmethyl)-3,7-dihydro-purine …
Matched Iupac: … 8-[(3R)-3-aminopiperidin-1-yl]-7-(but-2-yn-1-yl)-3-methyl-1-[(4-methylquinazolin-2-yl)methyl]-2,3,6,7 …
Matched Description: … Linagliptin was approved by the FDA on May 2, 2011[L9557]. ... Linagliptin is a DPP-4 inhibitor developed by Boehringer Ingelheim for the treatment of type II diabetes ... Linagliptin differs from other DPP-4 inhibitors in that it has a non-linear pharmacokinetic profile, …
Matched Categories: … Drugs Used in Diabetes ... Heterocyclic Compounds, 2-Ring …
Matched Iupac: … 8-[(3R)-3-aminopiperidin-1-yl]-7-(but-2-yn-1-yl)-3-methyl-1-[(4-methylquinazolin-2-yl)methyl]-2,3,6,7 …
Matched Description: … Linagliptin was approved by the FDA on May 2, 2011[L9557]. ... Linagliptin is a DPP-4 inhibitor developed by Boehringer Ingelheim for the treatment of type II diabetes ... Linagliptin differs from other DPP-4 inhibitors in that it has a non-linear pharmacokinetic profile, …
Matched Categories: … Drugs Used in Diabetes ... Heterocyclic Compounds, 2-Ring …
Delandistrogene moxeparvovec
Delandistrogene moxeparvovec is an adeno-associated virus vector-based gene therapy developed by Sarepta Therapeutics. It was granted accelerated approval by the FDA on June 22, 2023, as the first gene therapy to treat Duchenne Muscular Dystrophy (DMD). DMD is an X-linked genetic disorder characterized by mutations in the dystrophin gene, leading...
Approved
Investigational
Matched Description: … [L47026] DMD is an X-linked genetic disorder characterized by mutations in the dystrophin gene, leading ... to a deficiency in functional dystrophin protein. ... [A260256] DMD tends to be more prevalent in males. …
Guanadrel
Guanadrel is an antihypertensive agent and postganglionic adrenergic blocking agent.
Approved
Matched Iupac: … N''-({1,4-dioxaspiro[4.5]decan-2-yl}methyl)guanidine …
Matched Salts cas: … 22195-34-2 …
Matched Salts cas: … 22195-34-2 …
Influenza B virus B/Austria/1359417/2021 BVR-26 antigen (UV, formaldehyde inactivated)
A seasonally-specific component of the influenza vaccine. The influenza vaccine, also known as the "flu shot", is a vaccine that helps to protect against infection from influenza viruses. These vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which results in...
Approved
Matched Description: … This defense includes the production of humoral immunity through the development of antibodies and of ... A seasonally-specific component of the influenza vaccine. ... the virus) which results in an immunological defense against future exposure to the virus, or "antigen …
Displaying drugs 251 - 275 of 13792 in total